ASCO GI 2023 Conference Coverage

 

ASCO GI 2023 Conference Coverage
A

ASCO GI 2023 Promoting Multidisciplinary Care for Patients With Unresectable HCC: Findings From a Quality Improvement Initiative Across Two Community Cancer Centers

By ASCO GI 2023 Conference Coverage FEATURING Ari Baron
By ASCO GI 2023 Conference Coverage FEATURING Ari Baron
0 views
February 7, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Featured Video

15:07
Exelixis

Safety and Efficacy Data of a TKI Monotherapy in HCC

Feat. J. Mizrahi
Videos
07:46
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase II Clinical Trial to Study the Use of Cabozantini…

Feat. S. L. Chan
12:04
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Preliminary Efficacy and Correlative Results of the Pha…

Feat. K. Spencer
06:17
ASCO GI 2023 Conference Coverage

ASCO GI 2023 INTEGRATE IIa Randomised, Double-Blind, Phase III Study…

Feat. N. Pavlakis
06:25
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Overall Survival in Gastrointestinal Neuroendocrine Tum…

Feat. B. Laderian
05:13
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Primary Endpoint Results of a Randomized, Double-Blind,…

Feat. J. Furuse
13:21
ASCO GI 2023 Conference Coverage

ASCO GI 2023 TIMES Trial: Advancing Precision Immunotherapy for Gast…

Feat. D. Zeng
09:24
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Randomized Phase II VELO Clinical Trial: Panitumumab + …

Feat. S. Napolitano
11:02
ASCO GI 2023 Conference Coverage

ASCO GI 2023 3-Year Follow-Up From CheckMate 649: Nivo + Chemo vs. C…

Feat. Y. Y. Janjigian
30:57
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Final Surgical Salvage Results From OPERA Phase 3 Rando…

Feat. A. Sun Myint
08:54
ASCO GI 2023 Conference Coverage

ASCO GI 2023 CRC Highlights: Phase 3 SUNLIGHT & PARADIGM Trials

Feat. A. Venook
09:02
ASCO GI 2023 Conference Coverage

ASCO GI 2023: A Study of Pembro in Combination With Y90 Radioemboliz…

Feat. A. Somasundaram
05:56
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase II IMMULAB Trial: IO With Pembro in Combination W…

Feat. A. Vogel
05:26
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Results From the TAPUR Study: Pertuzumab + Trastuzumab …

Feat. T. Cannon
10:19
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Promoting Multidisciplinary Care for Patients With Unre…

Feat. A. Baron
07:46
ASCO GI 2023 Conference Coverage

FGFR2-Amplified Gastroesophageal Adenocarcinoma Is a Distinct Genomi…

Feat. B. Shariff
06:59
ASCO GI 2023 Conference Coverage

ASCO GI 2023 CCTG HE.1 - Phase 3 Study: Palliative RT for Symptomati…

Feat. L. Dawson
09:43
ASCO GI 2023 Conference Coverage

ASCO GI 2023 NRG/RTOG 1112 Randomized Phase 3 Study: Sorafenib vs. S…

Feat. L. Dawson
05:32
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Continuous Maintenance Capecitabine Dosing for Advanced…

Feat. R. Mukherji
20:09
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Debate: For a Fit Patient With Unresectable Metastatic …

Feat. K. Shiu
04:06
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase Ib OBERTO-201 Study: Evaluating Safety, Tolerabil…

Feat. J. Hubbard
06:08
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Survival Outcomes and Functional Results of VOLTAGE-A: …

Feat. Y. Tsukada
23:58
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Key Studies

Feat. R. Kim, R. Mehta
10:41
ASCO GI 2023 Conference Coverage

ASCO GI 2023 NAPOLI-3 Randomized, Open-Label Phase 3 Study: Liposoma…

Feat. Z. Wainberg
07:49
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Preliminary Clinical Results of the NERDY Study: Immuno…

Feat. A. Anna Prete
05:32
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase 3 Randomized SWOG 1815 Trial: Gemcitabine, Cispla…

Feat. R. Shroff
05:29
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase 3 BREAKWATER Study Safety Lead-In: Encorafenib + …

Feat. S. Kopetz
16:19
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Exploring Immunotherapy Combinations for DDR-Deficient …

Feat. K. Reiss Binder
08:15
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Zanidatamab + Chemo as 1L Treatment for HER2-Expressing…

Feat. E. Elimova
04:20
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Final Results of the Phase II RE-ExPEL Study: Ramucirum…

Feat. T. Oliver Götze
12:31
ASCO GI 2023 Conference Coverage

ASCO GI 2023 29-Month Follow-Up From CheckMate 648: Nivo + Chemo or …

Feat. K. Kato
07:20
ASCO GI 2023 Conference Coverage

ASCO GI 2023 ctDNA Informs Clinical Practice in Patients With Recurr…

Feat. R. Mehta
06:52
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Multicenter, Single-Arm, Multi-Cohort, Phase II INFINIT…

Feat. F. Pietrantonio
11:46
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Debate: For a Fit Patient With Unresectable Metastatic …

Feat. A. Shergill
09:47
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Neoadjuvant Immunotherapy in Localized dMMR CRC

Feat. S. Chakrabarti
09:12
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Comparative Analysis of the Molecular Profile and Tumor…

Feat. A. Alqahtani
04:46
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Confidence Study: Effectiveness & Safety of Encoraf…

Feat. A. Fernandez Montes
07:58
ASCO GI 2023 Conference Coverage

ASCO GI 2023 ctDNA Dynamics and Clinical Outcome in mCRC Patients Un…

Feat. M. Ghidini
09:41
ASCO GI 2023 Conference Coverage

ASCO GI 2023 New Prognostic Index of Advanced Gastric Cancer Using t…

Feat. D. Takahari
04:41
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Characterization of Long-Term Survivors in the TOPAZ-1 …

Feat. M. Bouattour
12:06
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Surgical Viewpoint on Non-Operative Management of Recta…

Feat. T. Konishi
27:37
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Expert Panel Discussion: Practice-Changing Updates

Feat. N. Uboha, A. Turk, K. Spencer, M. Cecchini
05:34
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Biomarker Study of The Phase III PARADIGM Trial: Negati…

Feat. K. Shitara
07:51
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase 3 SPOTLIGHT Study Primary Results: Zolbetuximab +…

Feat. K. Shitara
07:40
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Kinetics of Postoperative Circulating cfDNA and Impact …

Feat. S. Cohen
06:32
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Analysis of HLA Gene Expression in Patients With dMMR/M…

Feat. H. Lenz
07:43
ASCO GI 2023 Conference Coverage

ASCO GI 2023 ctDNA for Response Assessment in Patients With Anal Can…

Feat. J. Alvarez
06:55
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Evaluation of Clinical Benefit and PFS Ratio of Targete…

Feat. M. Niger
05:19
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase 3 STELLAR-303 Study: XL092 in Combination With At…

Feat. J. Hecht
10:26
ASCO GI 2023 Conference Coverage

Phase 3 Randomized SUNLIGHT Study: Trifluridine/Tipiracil + Bevacizu…

Feat. J. Tabernero
06:16
ASCO GI 2023 Conference Coverage

ASCO GI 2023 on Organ Preservation and Total Neoadjuvant Therapy for…

Feat. P. Romesser
06:55
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Results From a Phase 1a/1b Study: Botensilimab, a Novel…

Feat. A. El-Khoueiry
10:41
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Phase 2, Randomized, Double-Blind, Placebo-Controlled I…

Feat. A. El-Khoueiry
08:47
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Use of ctDNA for Early Assessment of Treatment Response…

Feat. P. Kasi
13:36
ASCO GI 2023 Conference Coverage

ASCO GI 2023 CTCs as Liquid Biopsies in Patients With mCRC vs. Other…

Feat. P. Kasi
06:32
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Randomized Phase III FIRE-4 study (AIO KRK-0114): Inves…

Feat. S. Stintzing
06:28
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Survival Analysis of the Phase II Randomized DEEPER Tri…

Feat. Y. Sunakawa